<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gast V</submitter><funding>ÅForsk</funding><funding>Chalmers University of Technology</funding><funding>VINNOVA</funding><pagination>36</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8905840</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>21(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Affibody molecules are synthetic peptides with a variety of therapeutic and diagnostic applications. To date, Affibody molecules have mainly been produced by the bacterial production host Escherichia coli. There is an interest in exploring alternative production hosts to identify potential improvements in terms of yield, ease of production and purification advantages. In this study, we evaluated the feasibility of Saccharomyces cerevisiae as a production chassis for this group of proteins.&lt;h4>Results&lt;/h4>We examined the production of three different Affibody molecules in S. cerevisiae and found that these Affibody molecules were partially degraded. An albumin-binding domain, which may be attached to the Affibody molecules to increase their half-life, was identified to be</pubmed_abstract><journal>Microbial cell factories</journal><pubmed_title>Engineering Saccharomyces cerevisiae for the production and secretion of Affibody molecules.</pubmed_title><pmcid>PMC8905840</pmcid><funding_grant_id>(Cellnova) 2017-02105</funding_grant_id><funding_grant_id>2019-649</funding_grant_id><pubmed_authors>Ekblad S</pubmed_authors><pubmed_authors>Tous Mohedano M</pubmed_authors><pubmed_authors>Molin M</pubmed_authors><pubmed_authors>Siewers V</pubmed_authors><pubmed_authors>Sandegren A</pubmed_authors><pubmed_authors>Gast V</pubmed_authors><pubmed_authors>Engqvist MKM</pubmed_authors><pubmed_authors>Thoren S</pubmed_authors><pubmed_authors>Dunas F</pubmed_authors><pubmed_authors>Guler R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Engineering Saccharomyces cerevisiae for the production and secretion of Affibody molecules.</name><description>&lt;h4>Background&lt;/h4>Affibody molecules are synthetic peptides with a variety of therapeutic and diagnostic applications. To date, Affibody molecules have mainly been produced by the bacterial production host Escherichia coli. There is an interest in exploring alternative production hosts to identify potential improvements in terms of yield, ease of production and purification advantages. In this study, we evaluated the feasibility of Saccharomyces cerevisiae as a production chassis for this group of proteins.&lt;h4>Results&lt;/h4>We examined the production of three different Affibody molecules in S. cerevisiae and found that these Affibody molecules were partially degraded. An albumin-binding domain, which may be attached to the Affibody molecules to increase their half-life, was identified to be</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-21T15:42:52.022Z</modification><creation>2025-04-21T15:42:52.022Z</creation></dates><accession>S-EPMC8905840</accession><cross_references><pubmed>35264156</pubmed><doi>10.1186/s12934-022-01761-0</doi></cross_references></HashMap>